EnGeneIC closes oversubscribed Series B financing
EnGeneIC, Ltd. , an emerging biopharmaceutical company focused on developing its proprietary EDV nanocell platform for the targeted delivery of cancer therapeutics, announced it has completed an oversubscribed $10 million Series B financing. The round …